Pular para o conteúdo
PodcastsEnsinoCore IM | Internal Medicine Podcast

Core IM | Internal Medicine Podcast

Core IM Team
Core IM | Internal Medicine Podcast
Último episódio

222 episódios

  • Core IM | Internal Medicine Podcast

    #214 Hyponatremia Management: A Core IM Classic

    12/08/2026 | 44min
    Throwback: Should you really fluid-restrict every patient with SIADH? When can IV fluids make hyponatremia better or worse? Are salt tabs actually doing enough? And what can urine studies tell you before you start treatment? Join us for a practical, physiology-driven approach to hyponatremia management, from fluids and solutes to loop diuretics and identifying the underlying cause. 

    🔹Sponsor: Search “Amazon Pharmacy Nationwide Home Delivery" in your EHR to get home delivery (often same-day). Learn more here.

    🔹Transcript and Shownotes

    6:46 | Pearl 1: Key Principles
    15:13 | Pearl 2: Fluids in hyponatremia
    26: 03 | Pearl 3: Solutes in hyponatremia management
    35:49 | Pearl 4: Lasix in hyponatremia management
    40:05 | Pearl 5: Etiologies

    Tags: CoreIM, Internal Medicine, Medical Education, SIADH, Fluid Restriction, Nephrology, Hospital Medicine, Urine Osmolality

    Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840

    Our Sponsors:
    * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com
    * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io
    * Check out FIGS: https://wearfigs.com

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Core IM | Internal Medicine Podcast

    #213 Hypertension First-Line Medications Troubleshooting | Bread & Butter Series

    28/07/2026 | 32min
    Why can lower-dose combinations be more effective and better tolerated than maximizing one medication? How to troubleshoot common challenges such as amlodipine edema, gout, electrolyte abnormalities, and the patient who says they cannot tolerate anything? Why ACT (ARBs, Calcium Channel Blockers, Thiazides) is the preferred first-line framework, and how to personalize medication choices based on comorbidities and side effects.

    🔹Sponsor: Oakstone CME
    Use the code "CORE325" for 25% off: https://www.coreimpodcast.com/MKSAP 

    🔹Transcript and Shownotes

    03:00 | Diagnosing Hypertension 
    04:10 | When to Start Combination Therapy Instead of Monotherapy 
    07:00 | Choosing First-Line Therapy Using the ACT Framework 
    13:23 | Why ARBs Are Often Preferred Over ACE Inhibitors 
    16:02 | Choosing the Right ARB: Candesartan vs Losartan 
    18:39 | Comparing Potency & Duration Across First-Line Antihypertensives 
    20:54 | Amlodipine Edema: Why It Happens and How to Fix It 
    23:54 | Thiazides: Practical Tips, Electrolyte Problems & Class-Killer Side Effects 
    29:33 | Managing Patients Who 'Can't Tolerate' Blood Pressure Medications 

    Tags: Hypertension Management, High Blood Pressure, Primary Care, Internal Medicine, Core IM

    Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840

    Our Sponsors:
    * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com
    * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io
    * Check out FIGS: https://wearfigs.com

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Core IM | Internal Medicine Podcast

    #212 Top 10 Highlights of the New Lipid Guidelines

    15/07/2026 | 23min
    Learn from primary care docs what has been practiced and changed from the 2026 ACC/AHA Lipid Guidelines! Learn how the new CPR framework (Calculate, Personalize, Reclassify) and PREVENT risk calculator change statin decisions, why LDL targets are back, and when to use Lp(a), ApoB, and coronary artery calcium (CAC) testing. Discover updated risk-enhancing factors, expanded indications for non-statin therapies, and practical strategies to personalize lipid management for both primary and secondary

    🔹Sponsor: Search “Amazon Pharmacy Nationwide Home Delivery" in your EHR to get home delivery (often same-day). Learn more here.

    🔹Transcript and Shownotes:  
    01:17 | Highlight #1 & #2: CPR and PREVENT Score
    03:14 | Highlight #3: Updated ASCVD Risk Categories Using the PREVENT Score
    05:30 | Highlight #4: LDL Targets Are Back
    07:20 | Highlight #5: High-Risk Conditions That Bypass the PREVENT Score
    08:41 | Highlight #6: Lp(a) Screening for Everyone
    11:51 | Highlight #7: When to Use ApoB Testing
    13:16 | Highlight #8: Reproductive Risk Factors
    15:29 | Highlight #9: Using CAC to Guide Statin Therapy
    19:09 | Highlight #10: Non-Statin Therapies

    Tags: CoreIM, Internal Medicine, Medical Education, Cholesterol, Statins, LDL, ASCVD, Preventive Cardiology, LpA, ApoB, CAC, ACC2026, Cardiology, PrimaryCare 

    Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840

    Our Sponsors:
    * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com
    * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io
    * Check out FIGS: https://wearfigs.com

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Core IM | Internal Medicine Podcast

    #211 Breaking Down MASLD vs. MASH and the MAESTRO-NASH & ESSENCE Trials: Beyond Journal Club Segment

    29/06/2026 | 33min
    MASLD affects nearly one in three adults worldwide, yet many patients remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? When is a FIB-4 enough, and when should we move to elastography or hepatology referral? And are we finally entering an era where we can meaningfully treat MASH?
    In this Beyond Journal Club episode, we unpack the evolving language of steatotic liver disease and take a close look at two major trials: MAESTRO-NASH studying resmetirom, the first FDA-approved liver-directed therapy for MASH, and ESSENCE, evaluating semaglutide in biopsy-confirmed disease.
    Along the way, we explore what these biopsy-based histologic endpoints really mean, why placebo responses were surprisingly high, and whether improvements in steatohepatitis and fibrosis will ultimately translate into better clinical outcomes for patients.
    This episode is for clinicians trying to understand where the field is headed, which patients deserve closer attention, and how metabolic liver disease is increasingly becoming part of everyday primary care and hospital medicine.

    🔹Sponsor: Oakstone CME
    Use the code "CORE325" for 25% off: https://www.coreimpodcast.com/MKSAP 

    🔹Transcript and Shownotes:  
    01:57 | Understanding MASLD as a Systemic Disease 
    05:45 | MASLD vs MASH vs Met-ALD: Spectrum Steatotic Liver Disease 
    08:55 | How to Screen for Fibrosis (FIB-4 & FibroScan) 
    16:15 | Lifestyle Treatment & Weight Loss Targets 
    19:00 | ESSENCE Trial: Semaglutide for MASH 
    21:58 | MAESTRO-NASH Trial: Resmetirom 
    27:27 | Future Treatments for MASH 
    30:51 | Key Takeaways for Clinicians 

    Tags: CoreIM, Internal Medicine, Medical Education, Hepatology, Fatty Liver Disease, Metabolic Dysfunction Associated Steatohepatitis, Nonalcoholic Fatty Liver Disease, Liver Fibrosis

    Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840

    Our Sponsors:
    * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com
    * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io
    * Check out FIGS: https://wearfigs.com

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Core IM | Internal Medicine Podcast

    #210 HTN in Dialysis: 5 Pearls Segment

    17/06/2026 | 25min
    What blood pressure should we target in patients on hemodialysis? Why volume control remains the foundation of treatment? How blood pressure targets differ from the general population. Learn practical pearls on medication timing around dialysis, drug dialyzability, antihypertensive selection, and strategies to prevent intradialytic complications while optimizing long-term outcomes. 

    🔹Sponsor: Search “Amazon Pharmacy Nationwide Home Delivery" in your EHR to get home delivery (often same-day). Learn more here. 

    🔹Transcript and Shownotes:  
    02: 19 | Pearl 1: Blood Pressure Targets 
    09: 40 | Pearl 2: Timing Medications and Dialyzability 
    15: 31 | Pearl 3 - Pharmacologic Management Nuances in Dialysis Patients 
    22: 57 | Putting It All Together: The Medication Hierarchy 

    Tags: CoreIM, Internal Medicine, Medical Education, Nephrology, ESRD, End-Stage Kidney Disease, Hypertension, Kidney Health, Dry Weight, Volume Overload

    Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840

    Our Sponsors:
    * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com
    * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io
    * Check out FIGS: https://wearfigs.com

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
Mais podcasts de Ensino
Sobre Core IM | Internal Medicine Podcast
Core Internal Medicine via following series: 5 Pearls || Clinically relevant pearls Mind the Gap || Why do we do what we do? Gray Matters || Management Reasoning Hoofbeats || Dissecting clinical reasoning At the Bedside || Explore everyday challenges
Site de podcast

Ouça Core IM | Internal Medicine Podcast, American English Podcast e muitos outros podcasts de todo o mundo com o aplicativo o radio.net

Obtenha o aplicativo gratuito radio.net

  • Guardar rádios e podcasts favoritos
  • Transmissão via Wi-Fi ou Bluetooth
  • Carplay & Android Audo compatìvel
  • E ainda mais funções
Aplicações
Social
v8.14.0 | © 2007-2026 radio.de GmbH
Generated: 8/14/2026 - 5:01:22 AM